Anti Smooth Muscle Antibody (ASMA)- Titres, in Visit Clinic

Normal ASMA (anti‑smooth muscle antibody) is considered negative — usually reported as <1:20 or <1:40 depending on the laboratory. Titers ≥1:80 are more suggestive of autoimmune hepatitis, while low‑positive or borderline results can be nonspecific. Reference ranges vary, so interpret ASMA in the context of clinical presentation and other liver autoantibodies and tests.

ASMA positive means anti-smooth muscle antibodies were detected in the blood. It often points to autoimmune liver disease (autoimmune hepatitis type 1) but can occur with other liver conditions, infections, drugs, or autoimmune disorders. It’s not diagnostic alone; doctors interpret it with symptoms, liver enzyme tests, immunoglobulin levels, imaging, and sometimes biopsy. Follow-up with a hepatologist or gastroenterologist is recommended.

The cost of an ASMA (anti–smooth muscle antibody) test varies by country and lab: in the United States it’s typically about $30–$150 out-of-pocket; in India around ₹300–₹1,200; in the UK testing is usually provided free via the NHS, while private clinics charge roughly £20–£70. Final price depends on the laboratory, location, and whether insurance or public healthcare covers it.

A 1/20 titer means antibodies (or other measured substances) are still detectable when the blood sample is diluted 1 part serum to 19 parts diluent — reported as a reciprocal titer of 20. It generally indicates a low antibody concentration compared with higher titers. Clinical significance depends on the specific assay and lab cutoff; interpretation requires test-specific reference ranges and clinical context.

A "good" titer means your antibody level meets the protective threshold for that specific infection, as defined by the lab and public-health guidelines. Protective cutoffs vary by disease—examples include hepatitis B surface antibody ≥10 mIU/mL and tetanus antitoxin ≥0.1 IU/mL. Compare results to the lab’s reference range and discuss interpretation or booster needs with your clinician.

Yes, autoimmune hepatitis is potentially serious. It is a chronic immune-mediated inflammation of the liver that can progress to fibrosis, cirrhosis, liver failure, and increased risk of liver cancer if untreated. With prompt diagnosis and immunosuppressive treatment most people respond well, but long-term monitoring and specialist care are often required to prevent complications.